“Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients With Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data”. SKIN The Journal of Cutaneous Medicine 2 (December 17, 2018): S78. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/474.